As Covid drug cash dwindles, Vigonvita targets new remedies
A Chinese biotech that made a name for itself by co-developing an anti-Covid drug has filed for a stock market listing to fund research into tackling other conditions Key Takeaways:…
BeiGene heads for profit milestone after hemorrhaging cash
With a blockbuster drug under its belt and another product approved for U.S. sale, the biopharma firm says it is on track to post an annual operating profit this year…
Junshi narrows its losses but delivers no cure for share price woes
The drug maker boosted sales of its core anti-cancer product in the first half of the year and reined in its research budget under a reform-minded CEO, but revenue momentum…
Hutchmed scores U.S. success with cancer drug, but profits still dip
The drug developer has reported sharply reduced profits, coming off an exceptionally high base last year, but sales of its key cancer medicine are accelerating in the United States Key…
BeiGene’s aggressive expansion brings revenue jolt
The innovative drug maker’s product revenue rose 82% to $747 million in the first quarter, with its star drug on pace to possibly net $2 billion for the year Key…
BeiGene still bleeding red ink despite blockbuster drug
The Chinese developer of next-generation cancer treatments is raking in huge returns from its flagship drug, but R&D and sales costs keep rising Key Takeaways: The Chinese biotech reported a…
Junshi hopes new scientist CEO can cure its woes
The biotech company has been dogged by multiple challenges recently, including declining revenue, ongoing losses and a recent rejection by one of its overseas partners Key Takeaways: Junshi has appointed…
